GlassScriptPhysician profile
David A Petty
NPI 1376877795
$11,931.74
in general payments reported to CMS, 2019-2025
39 companies · $2,391 in 2025
The $2,391 reported for 2025 was more than what a typical Allergy provider received nationally (typical 2025 total: $1,129).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $804 · 2020: $848 · 2021: $1,446 · 2022: $1,516 · 2023: $2,169 · 2024: $2,757 · 2025: $2,391.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,002 · Honoraria: $175 · Education: $97.99 · Consulting Fee: $42.52.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,002.00 |
| Honoraria | $175.00 |
| Education | $97.99 |
| Consulting Fee | $42.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,238.62 | 2019-2025 | Tezspire, Fasenra, Airsupra |
| Regeneron Healthcare Solutions, INC. | $1,409.18 | 2019-2025 | Dupixent |
| Grifols USA, LLC | $1,298.87 | 2019-2025 | Prolastin-C Liquid, Xembify, Gamunex-C |
| Glaxosmithkline, LLC. | $1,210.12 | 2019-2025 | Nucala, Trelegy Ellipta |
| Csl Behring | $1,060.46 | 2020-2025 | Hizentra, Haegarda |
| Genzyme Corporation | $583.00 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $537.43 | 2020-2025 | Takhzyro, Eohilia, Cuvitru |
| Biocryst US Sales Co., LLC | $385.89 | 2021-2025 | Orladeyo |
| Aimmune Therapeutics, INC. | $310.92 | 2021-2024 | |
| Novartis Pharmaceuticals Corporation | $297.94 | 2019-2025 | |
| Blueprint Medicines Corporation | $282.99 | 2022-2025 | Ayvakit |
| Mylan Specialty L.P. | $277.84 | 2019-2024 | Yupelri |
| Pharming Healthcare, INC. | $241.98 | 2019-2025 | Ruconest |
| Horizon Therapeutics Plc | $211.98 | 2019-2023 | Actimmune |
| Boehringer Ingelheim Pharmaceuticals, INC. | $205.31 | 2019-2023 | Spiriva Respimat |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $181.88 | 2020-2025 | |
| Amgen INC. | $121.35 | 2022-2025 | Actimmune, Tezspire |
| Teva Pharmaceuticals USA, INC. | $119.45 | 2021-2023 | Airduo Digihaler |
| Ionis Pharmaceuticals, INC. | $86.77 | 2025 | Dawnzera |
| Sunovion Pharmaceuticals INC. | $81.68 | 2019-2020 | |
| Optinose US, INC. | $81.42 | 2022-2024 | |
| Cycle Pharmaceuticals INC | $66.04 | 2024-2025 | Sajazir |
| Sanofi-Aventis U.S. LLC | $63.99 | 2024 | |
| Octapharma USA, INC. | $61.58 | 2019 | |
| Ars Pharmaceuticals Operations, INC. | $58.27 | 2025 | Neffy |
| Biocryst Pharmaceuticals, INC. | $52.81 | 2020 | |
| Lilly USA, LLC | $51.64 | 2024-2025 | Ebglyss |
| Greer Laboratories, INC. | $47.21 | 2024 | Palforzia |
| Adma Biomanufacturing LLC | $42.52 | 2023-2024 | |
| Uswm, LLC | $40.40 | 2021 | |
| Insmed, INC. | $31.78 | 2025 | Arikayce |
| X4 Pharmaceuticals, INC. | $29.93 | 2024 | Xolremdi |
| Verona Pharma, INC. | $28.84 | 2025 | Ohtuvayre |
| Circassia INC. | $27.97 | 2019-2020 | |
| Baxter Healthcare | $27.22 | 2025 | Hillrom - Vest System Model 105 Home Care |
| Tersera Therapeutics LLC | $24.98 | 2024 | Quzyttir |
| Merck Sharp & Dohme LLC | $17.68 | 2021 | |
| Kaleo, INC. | $17.41 | 2023 | Auvi-Q |
| Genentech USA, INC. | $16.39 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Petty listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.